FDA Orange Book · active-ingredient family
Leniolisib phosphate
Leniolisib phosphate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:JOENJA · NDA 217759
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
2
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| JOENJARLD | PHARMING | NDA 217759 | — | Mar 24, 2023 |
Marketing exclusivity (2)
- NCENew chemical entity exclusivity (5 years)
Mar 24, 2028
in 1 yr 9 mo
- ODE-430Orphan-drug exclusivity (7 years)
Mar 24, 2030
in 3 yr 10 mo
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8653092 | Feb 19, 2032 | in 5 yr 9 mo | SubstanceProduct |
Leniolisib phosphate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

